Reactions 1680, p300 - 2 Dec 2017 Intussusception: case report In a study, an infant [age and sex not stated] was described, who developed intussusception following treatment with RIX-4414 [monovalent rotavirus vaccine, Rotarix; route, dosage and time to reaction onset not stated]. The infant received RIX-4414 vaccine. The infant developed intussusception following administration of first dose of RIX-4414 vaccine. Despite confirmed intussusception episode after the first dose, the infant was given a second dose. No repeat episode of intussusception was observed after the second dose of the RIX-4414 vaccine. Author comment: "This case was one of 10 infantswho received a second dose despite confirmed intussusceptionepisode after their first dose." "The 2–3 fold elevated risk of intussusception after a first andsecond dose of RV1 demonstrated by our study, would resultin an estimated 21 additional intussusception cases each yearin England." Stowe J, et al. The risk of intussusception following monovalent rotavirus vaccination in England: A self-controlled case-series evaluation. Vaccine 34: 3684-3689, No. 32, 12 Jul 2016. Available from: URL: http://doi.org/10.1016/ j.vaccine.2016.04.050 - United Kingdom 803284730 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera